Current Oncology, Volume 17, Issue 1

This first issue of 2010 sees a gathering of momentum as Current Oncology transitions to hybrid-based publication. [...]

Objective: The cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5FU/LV)—the FOLFOX regimen—was compared with that of 5FU/LV alone as adjuvant therapy for patients with stage III colon cancer, from the perspective of th...

Approximately one third of cancers in women arise in the breast, making breast cancer the most commonly diagnosed cancer by far [...]

Background: Despite recommendations favouring review of cancer pathology specimens for patients being treated at an institution other than the one that produced the initial pathology report, data regarding discordance rates and their potential clinic...

Aim: Previous surveys have revealed wide variations in the management by radiation oncologists of non-small-cell lung cancer (NSCLC) in Canada. The aim of the present study was to determine the current patterns of practice for locally advanced and me...

Penile cancer is a rare cancer in developed countries, but it has a higher incidence in developing countries such as Asia, Africa, and South America [...]

We applied a learning methodology framework to assist in the threshold-based segmentation of non-small-cell lung cancer (NSCLC) tumours in positron-emission tomography–computed tomography (PET–CT) imaging for use in radiotherapy planning. Gated and s...

Background and Purpose: Palliative radiotherapy (PRT) is a routine part of oncology care in adult patients, but it is used much less frequently among children with incurable cancer. We surveyed Canadian pediatric oncologists to learn about their know...

Lung cancer is rare disease in patients under 25 years of age. It typically occurs in older patients with a history of tobacco use. This case concerns a 20-year-old man with no history of tobacco use who complained of several months of cough and lowe...

Capecitabine, an oral prodrug of 5-fluorouracil (5FU), has been integrated into the management of multiple cancer types because of convenience of administration and efficacy comparable with 5FU. Cardiotoxicity induced by 5FU—in particular angina—has...

Here we report a case of primary epithelioid angiosarcoma (EAS) of the breast occurring in a 30-year-old woman. Following fine-needle asspiration cytology (FNAC) and tru-cut biopsy, the patient was initially diagnosed with mammary carcinoma and there...

Background: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (TAC...

In recent years, various rna-based technologies have been under evaluation as potential next-generation cancer therapeutics. MicroRNAS (miRNAS), known to regulate the cell cycle and development, are deregulated in various cancers. Thus, they might se...

Hormone-suppression therapies are used for the treatment of breast cancer in the adjuvant and metastatic settings alike. However, side effects—including hot flashes—are frequently reported by patients as a cause of therapy discontinuation. This paper...

Aromatase inhibitors (AIS) are commonly used as adjuvant treatment in postmenopausal women with hormone receptor–positive early breast cancer. With both steroidal and nonsteroidal AIS, AI-induced arthralgia is frequently observed. The mechanism of AI...